Loading...
•
Mar 31, 2024
Abbott Q1 2024 Earnings Report
Abbott's Q1 2024 results reflected a strong start to the year, with sales driven by strong underlying base business performance and raised full-year sales and EPS guidance.
Key Takeaways
Abbott reported a 2.2% increase in sales, driven by strong performance in Medical Devices and Established Pharmaceuticals. The company raised its full-year sales and EPS guidance.
GAAP diluted EPS was $0.70 and adjusted diluted EPS was $0.98.
Full-year 2024 EPS guidance range was narrowed, projecting diluted EPS on a GAAP basis of $3.25 to $3.40 and adjusted diluted EPS of $4.55 to $4.70.
Full-year 2024 organic sales growth guidance range, excluding COVID-19 testing-related sales, was narrowed to 8.5% to 10.0%.
The fifth consecutive quarter of double-digit organic sales growth in the underlying base business was delivered.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Abbott projects second-quarter 2024 diluted earnings per share under GAAP of $0.69 to $0.73. Excluding specified items, projected adjusted diluted earnings per share would be $1.08 to $1.12 for the second quarter 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...